You are here

capmatinib

Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation

Xconomy

Thu, 05/7/20 - 12:29 am

non-small cell lung cancer

#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions

Endpoints

Mon, 04/27/20 - 09:43 am

FDA Speeds Up Examination of 5 Drugs with Priority Review

BioSpace

Thu, 02/13/20 - 12:24 am

priority review

belantamab mafodotin

Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs

Endpoints

Tue, 02/11/20 - 10:28 am

prioirty review

non-small cell lung cancer

#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients

Endpoints

Tue, 06/4/19 - 12:16 pm

non-small cell lung cancer